Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy.
Quiros-Roldan E, Torti C, Lapadula G, Ladisa N, Micheli V, Patroni A, Cusato M, Pierotti P, Tirelli V, Uccelli MC, Di Giambenedetto S, Castelnuovo F, Gargiulo F, Manca N, Carosi G; RADAR-Master Study Group. Quiros-Roldan E, et al. Among authors: patroni a. AIDS Patient Care STDS. 2007 Feb;21(2):92-9. doi: 10.1089/apc.2005.0037. AIDS Patient Care STDS. 2007. PMID: 17328658 Clinical Trial.
Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting.
Torti C, Casari S, Palvarini L, Quiros-Roldan E, Moretti F, Leone L, Patroni A, Castelli F, Ripamonti D, Tramarin A, Carosi G. Torti C, et al. Among authors: patroni a. Health Policy. 2003 Sep;65(3):261-7. doi: 10.1016/s0168-8510(03)00002-2. Health Policy. 2003. PMID: 12941493
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.
Torti C, Quiros-Roldan E, Regazzi M, De Luca A, Mazzotta F, Antinori A, Ladisa N, Micheli V, Orani A, Patroni A, Villani P, Lo Caputo S, Moretti F, Di Giambenedetto S, Castelnuovo F, Maggi P, Tinelli C, Carosi G; RADAR-MASTER Study Group. Torti C, et al. Among authors: patroni a. Clin Infect Dis. 2005 Jun 15;40(12):1828-36. doi: 10.1086/429917. Epub 2005 May 12. Clin Infect Dis. 2005. PMID: 15909273 Clinical Trial.
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
Torti C, Uccelli MC, Quiros-Roldan E, Gargiulo F, Tirelli V, Lapadula G, Regazzi M, Pierotti P, Tinelli C, De Luca A, Patroni A, Manca N, Carosi G. Torti C, et al. Among authors: patroni a. J Clin Virol. 2006 Apr;35(4):414-9. doi: 10.1016/j.jcv.2005.10.001. Epub 2005 Nov 8. J Clin Virol. 2006. PMID: 16280255 Clinical Trial.
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients.
Torti C, Lapadula G, Uccelli MC, Quiros-Roldan E, Regazzi M, Ladisa N, Micheli V, Orani A, Patroni A, Caputo SL, Tirelli V, Di Giambenedetto S, Cologni G, Costarelli S, Gargiulo F, Manca N, Carosi G; RADAR Study Group of MASTER Cohort. Torti C, et al. Among authors: patroni a. Int J Antimicrob Agents. 2007 Feb;29(2):185-90. doi: 10.1016/j.ijantimicag.2006.08.015. Epub 2006 Oct 2. Int J Antimicrob Agents. 2007. PMID: 17011754
Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switch.
Tomasoni LR, Patroni A, Torti C, Paraninfo G, Gargiulo F, Quiros-Roldan E, Uccelli MC, Airò P, Tinelli C, Carosi G, Castelli F; Brescia-MASTER Study Group. Tomasoni LR, et al. Among authors: patroni a. HIV Clin Trials. 2003 Sep-Oct;4(5):311-23. doi: 10.1310/FGMF-Y0LY-DMX8-371V. HIV Clin Trials. 2003. PMID: 14583847
Lopinavir plasma levels in salvage regimes by a population of highly active antiretroviral therapy-treated HIV-1-positive patients.
Torti C, Quiros-Roldan E, Tirelli V, Regazzi-Bonora M, Moretti F, Pierotti P, Orani A, Maggi P, Cargnel A, Patroni A, De Luca A, Carosi G; RADAR Study Group of the Master Cohort. Torti C, et al. Among authors: patroni a. AIDS Patient Care STDS. 2004 Nov;18(11):629-34. doi: 10.1089/apc.2004.18.629. AIDS Patient Care STDS. 2004. PMID: 15633260 Clinical Trial.
43 results